Search - tctmd.com

Displaying 261 - 280 of 498

Sort: Relevancy | Date

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Conference News THT 2022

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Caitlin E. Cox

February 07, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Daily News

SCAI SHOCK: Update Refines Cardiogenic Shock Classification

Caitlin E. Cox

January 31, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Features

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

Todd Neale

January 13, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

Advertisement

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

February 2022 News Roundup

SCAI SHOCK: Update Refines Cardiogenic Shock Classification

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

January 2022 News Roundup

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 2021 News Roundup

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Canagliflozin Improves Quality of Life in HF Patients

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content